Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 2,274 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $118.37, for a total transaction of $269,173.38. Following the completion of the transaction, the director now directly owns 519,074 shares in the company, valued at approximately $61,442,789.38. The trade was a 0.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kevin Charles Gorman also recently made the following trade(s):

• On Thursday, February 13th, Kevin Charles Gorman sold 5,844 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36.
• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.92, for a total transaction of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX traded down $1.85 during midday trading on Friday, reaching $115.02. 1,479,784 shares of the company traded hands, compared to its average volume of 952,604. The firm has a market capitalization of $11.65 billion, a price-to-earnings ratio of 34.96 and a beta of 0.33. The company has a fifty day moving average price of $137.83 and a 200 day moving average price of $130.54. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. On average, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. HC Wainwright cut their target price on Neurocrine Biosciences from $190.00 to $185.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Bank of America decreased their price objective on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday, February 7th. UBS Group raised their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a research note on Thursday, January 30th. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Finally, StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $166.90.

Hedge Funds Weigh In On Neurocrine Biosciences

Several large investors have recently added to or reduced their stakes in the company. Dodge & Cox raised its position in Neurocrine Biosciences by 134.2% in the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $115,193,000. Wellington Management Group LLP lifted its holdings in shares of Neurocrine Biosciences by 102.9% in the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after purchasing an additional 739,199 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Neurocrine Biosciences by 2,759.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock valued at $100,705,000 after purchasing an additional 711,970 shares in the last quarter. Finally, State Street Corp raised its holdings in Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock worth $593,186,000 after acquiring an additional 539,936 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.